title: Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody.
abstract: Advanced chemotherapy-resistant ovarian cancer has a poor prognosis, thus requiring new therapeutic modalities. A complete clinical remission, using two cycles of 131I-labeled murine MN-14 anti-CEA monoclonal antibody (MAb), given intravenously, is reported in a patient with advanced ovarian cancer refractory to paclitaxel (Taxol) therapy. The patient first received radioimmunotherapy with approximately 74 mCi 131I-MN-14 IgG, followed 4 mo later by a similar dose of radiolabeled MAb. A partial remission was seen by CT 1 mo after the first radioimmunotherapy, and a further objective response was documented after the second radioimmunotherapy. CT scans performed 6 and 11 mo after the second radioimmunotherapy showed stable and minimal residual changes. However, a whole-body PET scan with [18F]fluorodeoxyglucose (FDG-PET) was negative in these regions. The CA-125 also decreased to only 13 U/ml, compared to the baseline value of 7700 U/ml. Based on CT, FDG-PET, serum CA-125 and physical exam, the patient was in complete clinical remission for 8 mo when the CA-125 levels rose. CT also showed a new suspicious lesion, presumably a peritoneal implant. No toxicity was seen after the first injection, and only Grade 1 thrombocytopenia and Grade 2 leukopenia developed after the second injection, both reversing within 6 wk. This is a report of a complete clinical remission with radiolabeled anti-CEA antibodies in a patient with chemotherapy-refractive metastatic ovarian cancer.
authors.affiliation: Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109-0023, USA.
authors.forename: M
authors.initials: M
authors.lastname: Juweid
authors.forename: R M
authors.initials: RM
authors.lastname: Sharkey
authors.forename: A
authors.initials: A
authors.lastname: Alavi
authors.forename: L C
authors.initials: LC
authors.lastname: Swayne
authors.forename: T
authors.initials: T
authors.lastname: Herskovic
authors.forename: D
authors.initials: D
authors.lastname: Hanley
authors.forename: A D
authors.initials: AD
authors.lastname: Rubin
authors.forename: M
authors.initials: M
authors.lastname: Pereira
authors.forename: D M
authors.initials: DM
authors.lastname: Goldenberg
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal; D018394:CA-125 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000276:immunology; D003847:Deoxyglucose / Q000031:analogs & derivatives; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D012074:Remission Induction; D016879:Salvage Therapy; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D018394:CA-125 Antigen; D002272:Carcinoembryonic Antigen; D005462:Fluorine Radioisotopes; D007457:Iodine Radioisotopes; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose